Pemphigus Vulgaris (PV) Pipeline Analysis report covers 8 drugs currently in different phases of development. Pemphigus Vulgaris is a rare, autoimmune disorder characterized by painful blistering of the skin and mucous membranes. Organs generally affected by the disease are mouth, eyes, nose, throat, lungs, and genitals. Symptoms include the painful blisters on the skin or mouth along with the oozing, crusting, or peeling at the blister site. The disease is caused when the immune system mistakenly produces the antibodies against the proteins in healthy skin and mucous membranes. Therapy for Pemphigus Vulgaris includes treatment with corticosteroids or other immune-suppressing drugs.
The report provides Pemphigus Vulgaris (PV) treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases, and journals among others have been taken into consideration while conducting secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Argenx BVBA, Alexion Pharmaceuticals, Inc and Novartis AG among others.
Scope:
· By Company
· By Phase
· By Molecule Type
· By Region
· By Route of Administration
* There may be changes in the final report as per data availability.